Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases

P Cassier, J Schneider, A Italiano, A Hollebecque, R Heist, T Shimizu, S Y Kim, A Spira, R Cosman, G Sherwood, S Patel, Y-C Kim, W Iams, M Khalil, A Fink, Y Lin, M Willard, M Socinski, S Kurz · Pneumologie · 2026 · Heft S 01 S 01 · S. S164-S165